Choice Broking on Friday said the 100 per cent US tariff on branded and patented pharmaceutical products could negatively impact Indian pharmaceutical exporters, as the US represents the largest market for Indian pharma, accounting for approximately 35 per cent of exports, valued at $10 billion in FY25.

While the tariff primarily targets branded drugs, Choice Broking said there is ambiguity over whether complex generics and specialty medicines might also be affected, which could pose challenges for companies relying on US exports. Advertisement

"However, firms with manufacturing plants under construction in the U.S. will be exempt, offering an opportunity to mitigate tariff exposure," it said.

US President Donald Trump has announced a 100 per cent import tariff on branded or patented

See Full Page